Publications by authors named "Muneeza Ali"
Zuranolone and its role in treating major depressive disorder: a narrative review.
Horm Mol Biol Clin Investig
June 2023
Article Synopsis
- - Major Depressive Disorder (MDD) is a common mood disorder affecting 264 million people globally, characterized by a persistent low mood and loss of interest lasting over two weeks, as defined by DSM-V criteria.
- - Zuranolone (SAGE-217) is being studied as a potential treatment for MDD, acting as a neuroactive steroid that enhances GABA receptor activity; it’s administered orally for two weeks and aims to improve depressive symptoms.
- - Early trials, including a phase II trial, show Zuranolone significantly reduced depression scores and was well tolerated, leading to further phase III trials to assess its safety and efficacy in treating MDD.
The second year of the COVID-19 (coronavirus disease) pandemic has seen the need to identify and assess the long-term consequences of a SARS-CoV-2 infection on an individual's overall wellbeing, including adequate cognitive functioning. 'Cognitive COVID' is an informal term coined to interchangeably refer to acute changes in cognition during COVID-19 and/or cognitive sequelae with various deficits following the infection. These may manifest as altered levels of consciousness, encephalopathy-like symptoms, delirium, and loss of various memory domains.
View Article and Find Full Text PDFPostpartum depression (PPD) is defined as the onset of major depressive disorder in mothers, occurring during pregnancy or within 4 weeks post-delivery. With 7% of pregnancy-related death in the United States owing to mental health conditions, including PPD, and a global prevalence of 12%, PPD is a growing public health concern. In 2019, the Food and Drug Administration (FDA) approved brexanolone, an exogenous analog of allopregnanolone, as the first ever drug to be specifically indicated for treating patients with PPD.
View Article and Find Full Text PDF